Press Releases

Press Releases
Date Title and Summary View
May 17, 2017 Presentations will include multiple solid tumor and blood cancers while highlighting the value of innovative research SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) today announced that data from a broad range of company-sponsored and investigator-initiated studies ...
May 6, 2017 - Preliminary results show that treatment with investigational drug luspatercept achieves meaningful erythroid response rates and transfusion independence in first-line, lower-risk myelodysplastic syndromes patients - - Celgene and Acceleron plan to initiate a Phase 3 trial in first-line,...
May 3, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) plans to present at three upcoming investor conferences where Celgene management will provide an overview of the Company. The conferences will be webcast live and will be available in the Investor Relations section of the Company's website at www.c...
Apr 27, 2017 - Net Product Sales of $2.95B in Q1:17; Increased 18% Y/Y - REVLIMID® Net Product Sales of $1.9B in Q1:17; Increased 20% Y/Y - Raising 2017 EPS Guidance - Positive phase II STEPSTONE data with ozanimod in Crohn's disease; Phase III trial initiation pla...
Apr 3, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) has received a Paragraph IV Notice Letter advising that Teva Pharmaceuticals USA, Inc. submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) seeking authorization from the FDA to manufacture an...
Apr 3, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, April 27, 2017 at 9 a.m. ET to discuss first quarter 2017 financial and operational results. The webcast can be accessed from the Investor Relations page at www.celgene.com. ...
Mar 5, 2017 Data from UNVEIL, the first trial of patients with moderate plaque psoriasis (BSA 5-10 percent) who were naïve to systemic and biologic therapy, presented at American Academy of Dermatology Congress OTEZLA demonstrated significant improvements versus placebo for the primary and key secondary ...
Mar 3, 2017 UNVEIL evaluated the efficacy and safety of oral OTEZLA at 16 weeks in patients with moderate plaque psoriasis who were naïve to systemic and biologic therapy SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that findings from ongoing clinical t...
Mar 1, 2017 PDUFA date set for Aug. 30, 2017 SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals (NASDAQ:AGIO) today announced that the U.S. Food and Drug Administration (FDA) has accepted Celgene's New Drug Application (NDA) for enasidenib ...
Feb 27, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) plans to present at two upcoming investor conferences where Celgene management will provide an overview of the Company. The conferences will be webcast live and will be available in the Investor Relations section of the Company's website at www.cel...
FirstPrevious
2
... NextLast
Add to Briefcase = add release to Briefcase